Imidazo-pyridine derivatives as ligands for gaba receptors
申请人:Goodacre Charles Simon
公开号:US20050165048A1
公开(公告)日:2005-07-28
A class of 8-fluoro-3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a —NH— or —OCH
2
— linkage, being selective ligands for GABA
A
receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
Imidazo-pyridine derivatives as ligands for GABA receptors
申请人:Merck Sharp & Dohme Limited
公开号:US07279580B2
公开(公告)日:2007-10-09
A class of 8-fluoro-3-phenylimidazo[1,2-α]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a —NH— or —OCH2— linkage, being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
N-HETEROAROMATIC AMIDE DERIVATIVES FOR TREATMENT OF CANCER
申请人:Shenzhen Forward Pharmaceuticals Co., Ltd.
公开号:EP3950686A1
公开(公告)日:2022-02-09
The present application relates to azaaromatic amide derivatives for the treatment of cancer. Specifically, the present application relates to a preparation method and use of azaaromatic amide derivatives. The present application relates to azaaromatic amide derivatives and anilino-pyrimidine compounds represented by formula (I), formula (II), formula (III), formula (IV), and formula (V), and pharmaceutically acceptable salts thereof; the compounds or salts thereof can be used to treat or prevent a disease or disorder by regulating certain mutant forms of epidermal growth factor receptors. The present application also relates to a pharmaceutical composition comprising the compounds or salts thereof, and a method for treating various diseases mediated by EGFR, or HER2, or HER4 by using the compounds and salts thereof.
Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
申请人:Nimbus Saturn, Inc.
公开号:US11078201B2
公开(公告)日:2021-08-03
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
本发明提供了用于抑制 HPK1 和治疗 HPK1 介导的疾病的化合物、其组合物和使用方法。
Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
申请人:Nimbus Saturn, Inc.
公开号:US11021481B2
公开(公告)日:2021-06-01
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.